Nutrition Diva Have GLP-1s become the new Botox?
7 snips
Jan 28, 2026 Ted Kyle, pharmacist and founder of Kanchian Health who promotes informed and equitable obesity care. He discusses telehealth’s surge in prescribing GLP-1s and whether easy access risks quality or creates pill mills. They examine compounded peptides, microdosing hype, oral semaglutide as maintenance, and what responsible telemedicine for weight care should include.
AI Snips
Chapters
Transcript
Episode notes
Telehealth Expands Access But Risks Lowering Care
- Telehealth's rapid GLP-1 access improves convenience but risks lowering care standards when focused only on prescriptions.
- Monica Reinagel and Ted Kyle warn access must pair with thorough medical oversight and behavioral support.
Weight Regain After Stopping Is Common
- GLP-1s treat obesity as a chronic disease, not a short-term weight-loss tool.
- Stopping therapy usually leads to weight regain because biology defends prior weight levels.
Oral Semaglutide Could Improve Maintenance Care
- New oral semaglutide may lower cost and improve acceptability versus injectables.
- Ted Kyle suggests oral options could help patients accept long-term maintenance therapy.